Impact of initial imaging with gallium‐68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors

2019 ◽  
Vol 121 (3) ◽  
pp. 480-485 ◽  
Author(s):  
Angelena Crown ◽  
Flavio G. Rocha ◽  
Preethi Raghu ◽  
Bruce Lin ◽  
Gayle Funk ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Diagnosis And Management ◽  
Pet Ct ◽  
Initial Imaging ◽  
Gallium 68

Gallium-68-DOTA-NOC PET/CT of Patients With Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Single-Center Study

2011 ◽  
Vol 197 (5) ◽  
pp. 1221-1228 ◽  
Author(s):  
Niraj Naswa ◽  
Punit Sharma ◽  
Abhishek Kumar ◽  
Aftab Hasan Nazar ◽  
Rakesh Kumar ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Single Center ◽  
Gastroenteropancreatic Neuroendocrine Tumors ◽  
Pet Ct ◽  
Single Center Study ◽  
Gallium 68 ◽  
Center Study

Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors (NETs): A sequential case series.

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 379-379
Author(s):  
Hagen F. Kennecke ◽  
Preethi Raghu ◽  
Bruce Lin ◽  
Gayle L. Funk ◽  
Adnan Alseidi ◽  
...  
Keyword(s):  
Metastatic Disease ◽  
Imaging Modality ◽  
Case Series ◽  
Lesion Detection ◽  
Unknown Primary ◽  
Somatostatin Analogue ◽  
Diagnosis And Management ◽  
Pet Ct ◽  
Initial Imaging ◽  
The Impact

379 Background: Somatostatin analogue functional imaging with Ga-68 Dotatate PET/CT has demonstrated superiority in lesion detection in patients with NETs. The effect of this novel imaging modality on US clinical practice and its usefulness in different types of NETs is not well described. We describe the impact of initial NETSPOT imaging on diagnosis and management in NET patients at a large urban medical center. Methods: Consecutive patients diagnosed with NETs and referred to our institution who received an initial Ga-68 Dotatate PET/CT between 07/2017-09/2018 were included. Imaging was reviewed and compared to prior available CT, MRI, and/or In-111 Pentetreotide scans. Results: Among 101 patients, 51/50 were female/male, tumor origins were gastroenteropancreatic (GEP) (75%), Unknown Primary (UP) (13%), lung (8%), thymic (2%), and other (2%). All tumors were histologically well/moderately differentiated and 37/51/3/10 were G1/G2/G3/Unknown, respectively. Initial imaging with Ga-68 Dotatate PET/CT revealed additional metastatic disease in 37 of 77(48%) patients with prior evidence of metastatic disease. Most common sites were distant lymph nodes (18), bone (15) and liver (9), peritoneal/pleural (4). A previously UP tumor was identified in 3 patients. No patients with metastatic lung carcinoids (6 atypical, 2 typical) or thymic NETs (2 atypical/G2) NETs had evidence of Ga-68 Dota PET/CT uptake above reference liver SUV levels. Results of imaging altered patient management as follows: 14 initiated systemic therapy due to documentation of progression, in 6 surgical therapy was altered, in 4 biopsy/other management was changed. In 11 patients with no tumor Ga-68 Dotatate uptake, decisions about use of PRRT and somatostatin analogues was altered. Conclusions: In this series, Ga-68 Dotatate PET/CT altered diagnosis and management in 35/101 NET patients. Among GEP and UP NETs, Dotatate imaging diagnosed primarily new nodal, bone, liver and pleural/peritoneal metastases missed by other imaging modalities. Results support the routine use of Ga-68 Dotatate PET/CT in the care of patients with advanced and early stage NETS.

scholarly journals Concomitant lung and gastroenteropancreatic neuroendocrine tumors and the value of gallium-68 PET/CT

2011 ◽  
Vol 11 (1) ◽  
pp. 179-183 ◽  
Author(s):  
Daniel Kaemmerer ◽  
Karl Khatib-Chahidi ◽  
Richard Paul Baum ◽  
Dieter Horsch ◽  
Norbert Presselt ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Gastroenteropancreatic Neuroendocrine Tumors ◽  
Pet Ct ◽  
Gallium 68

ACR Practice Parameter for the Performance of Gallium-68 DOTATATE PET/CT for Neuroendocrine Tumors

2018 ◽  
Vol 43 (12) ◽  
pp. 899-908 ◽  
Author(s):  
Rathan M. Subramaniam ◽  
Marques L. Bradshaw ◽  
Kenneth Lewis ◽  
Daniella Pinho ◽  
Chirayu Shah ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Practice Parameter ◽  
Pet Ct ◽  
Gallium 68

Comparison of Fluorine(18)-fluorodeoxyglucose and Gallium(68)-citrate PET/CT in patients with tuberculosis

2019 ◽  
Vol 58 (05) ◽  
pp. 371-378
Author(s):  
Alfred O. Ankrah ◽  
Ismaheel O. Lawal ◽  
Tebatso M.G. Boshomane ◽  
Hans C. Klein ◽  
Thomas Ebenhan ◽  
...  
Keyword(s):  
Tracer Uptake ◽  
Pet Ct ◽  
The Mean ◽  
18F Fdg ◽  
Definition Of ◽  
Gallium 68 ◽  
Attending Physician ◽  
Pet Scans ◽  
The Brain

Abstract 18F-FDG and 68Ga-citrate PET/CT have both been shown to be useful in the management of tuberculosis (TB). We compared the abnormal PET findings of 18F-FDG- and 68Ga-citrate-PET/CT in patients with TB. Methods Patients with TB on anti-TB therapy were included. Patients had a set of PET scans consisting of both 18F-FDG and 68Ga-citrate. Abnormal lesions were identified, and the two sets of scans were compared. The scan findings were correlated to the clinical data as provided by the attending physician. Results 46 PET/CT scans were performed in 18 patients, 11 (61 %) were female, and the mean age was 35.7 ± 13.5 years. Five patients also had both studies for follow-up reasons during the use of anti-TB therapy. Thirteen patients were co-infected with HIV. 18F-FDG detected more lesions than 68Ga-citrate (261 vs. 166, p < 0.0001). 68Ga-citrate showed a better definition of intracerebral lesions due to the absence of tracer uptake in the brain. The mean SUVmax was higher for 18F-FDG compared to 68Ga-citrate (5.73 vs. 3.01, p < 0.0001). We found a significant correlation between the SUVmax of lesions that were determined by both tracers (r = 0.4968, p < 0.0001). Conclusion Preliminary data shows 18F-FDG-PET detects more abnormal lesions in TB compared to 68Ga-citrate. However, 68Ga-citrate has better lesion definition in the brain and is therefore especially useful when intracranial TB is suspected.

scholarly journals Prospective study of dynamic whole-body 68Ga-DOTATOC-PET/CT acquisition in patients with well-differentiated neuroendocrine tumors

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Philippe Thuillier ◽  
David Bourhis ◽  
Jean Philippe Metges ◽  
Romain Le Pennec ◽  
Karim Amrane ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Linear Relation ◽  
Whole Body ◽  
Pet Ct ◽  
Non Linear ◽  
Well Differentiated ◽  
Analog Systems ◽  
Pet System ◽  
Dynamic Acquisition ◽  
Linear Regressions

AbstractTo present the feasibility of a dynamic whole-body (DWB) 68Ga-DOTATOC-PET/CT acquisition in patients with well-differentiated neuroendocrine tumors (WD-NETs). Sixty-one patients who underwent a DWB 68Ga-DOTATOC-PET/CT for a histologically proven/highly suspected WD-NET were prospectively included. The acquisition consisted in single-bed dynamic acquisition centered on the heart, followed by the DWB and static acquisitions. For liver, spleen and tumor (1–5/patient), Ki values (in ml/min/100 ml) were calculated according to Patlak's analysis and tumor-to-liver (TLR-Ki) and tumor-to-spleen ratios (TSR-Ki) were recorded. Ki-based parameters were compared to static parameters (SUVmax/SUVmean, TLR/TSRmean, according to liver/spleen SUVmean), in the whole-cohort and according to the PET system (analog/digital). A correlation analysis between SUVmean/Ki was performed using linear and non-linear regressions. Ki-liver was not influenced by the PET system used, unlike SUVmax/SUVmean. The regression analysis showed a non-linear relation between Ki/SUVmean (R2 = 0.55,0.68 and 0.71 for liver, spleen and tumor uptake, respectively) and a linear relation between TLRmean/TLR-Ki (R2 = 0.75). These results were not affected by the PET system, on the contrary of the relation between TSRmean/TSR-Ki (R2 = 0.94 and 0.73 using linear and non-linear regressions in digital and analog systems, respectively). Our study is the first showing the feasibility of a DWB 68Ga-DOTATOC-PET/CT acquisition in WD-NETs.

scholarly journals Management Impact of 68Ga-DOTATATE PET/CT in Neuroendocrine Tumors

2021 ◽  
Author(s):  
Redmond-Craig Anderson ◽  
Erik M. Velez ◽  
Bhushan Desai ◽  
Hossein Jadvar
Keyword(s):  
Neuroendocrine Tumors ◽  
Pet Ct

scholarly journals Impact of PET data driven respiratory motion correction and BSREM reconstruction of 68Ga-DOTATATE PET/CT for differentiating neuroendocrine tumors (NET) and intrapancreatic accessory spleens (IPAS)

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Virginia Liberini ◽  
Fotis Kotasidis ◽  
Valerie Treyer ◽  
Michael Messerli ◽  
Erika Orita ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Motion Correction ◽  
Accessory Spleen ◽  
Pancreatic Neuroendocrine Tumor ◽  
Reconstruction Algorithm ◽  
Data Driven ◽  
Operating Characteristics ◽  
Quantitative Pet ◽  
Pet Ct ◽  
Accessory Spleens

AbstractTo evaluate whether quantitative PET parameters of motion-corrected 68Ga-DOTATATE PET/CT can differentiate between intrapancreatic accessory spleens (IPAS) and pancreatic neuroendocrine tumor (pNET). A total of 498 consecutive patients with neuroendocrine tumors (NET) who underwent 68Ga-DOTATATE PET/CT between March 2017 and July 2019 were retrospectively analyzed. Subjects with accessory spleens (n = 43, thereof 7 IPAS) and pNET (n = 9) were included, resulting in a total of 45 scans. PET images were reconstructed using ordered-subsets expectation maximization (OSEM) and a fully convergent iterative image reconstruction algorithm with β-values of 1000 (BSREM1000). A data-driven gating (DDG) technique (MOTIONFREE, GE Healthcare) was applied to extract respiratory triggers and use them for PET motion correction within both reconstructions. PET parameters among different samples were compared using non-parametric tests. Receiver operating characteristics (ROC) analyzed the ability of PET parameters to differentiate IPAS and pNETs. SUVmax was able to distinguish pNET from accessory spleens and IPAs in BSREM1000 reconstructions (p < 0.05). This result was more reliable using DDG-based motion correction (p < 0.003) and was achieved in both OSEM and BSREM1000 reconstructions. For differentiating accessory spleens and pNETs with specificity 100%, the ROC analysis yielded an AUC of 0.742 (sensitivity 56%)/0.765 (sensitivity 56%)/0.846 (sensitivity 62%)/0.840 (sensitivity 63%) for SUVmax 36.7/41.9/36.9/41.7 in OSEM/BSREM1000/OSEM + DDG/BSREM1000 + DDG, respectively. BSREM1000 + DDG can accurately differentiate pNET from accessory spleen. Both BSREM1000 and DDG lead to a significant SUV increase compared to OSEM and non-motion-corrected data.

Sign in / Sign up

Export Citation Format

Share Document